--- title: "A Look At Insulet (PODD) Valuation After Strong Q1 Results And Raised Revenue Guidance" type: "News" locale: "en" url: "https://longbridge.com/en/news/286451912.md" description: "Insulet (PODD) reported strong Q1 results with revenue of $761.7 million and net income of $91.1 million, raising its 2026 revenue guidance. Despite this, its share price has dropped 24.8% in the past month and 47.4% year-to-date, indicating market reassessment of growth expectations. Analysts suggest the stock is undervalued, with a fair value of $326 compared to its current price of $148.84. The company is positioned for growth in the diabetes device market, but risks include potential device issues and competition. Investors are encouraged to evaluate the mixed signals in valuation models." datetime: "2026-05-14T18:03:09.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286451912.md) - [en](https://longbridge.com/en/news/286451912.md) - [zh-HK](https://longbridge.com/zh-HK/news/286451912.md) --- # A Look At Insulet (PODD) Valuation After Strong Q1 Results And Raised Revenue Guidance Insulet (PODD) attracted attention after reporting first quarter revenue of US$761.7 million and net income of US$91.1 million, while raising full year 2026 revenue guidance and outlining higher second quarter growth expectations. See our latest analysis for Insulet. Despite the strong first quarter results, higher 2026 guidance and an active buyback program, Insulet’s share price has fallen 24.8% over the past month and 47.4% year to date, with 1 year total shareholder return down 53.7%. This points to fading momentum and a market reassessment of risk and future growth expectations. If advances in diabetes technology interest you, it can be useful to widen the lens and review other healthcare stocks using artificial intelligence, starting with the 33 healthcare AI stocks With Insulet’s share price sharply lower, while analyst targets and intrinsic value estimates sit well above the market, the key question now is whether investors are overlooking its potential or correctly pricing in future growth. ## Most Popular Narrative: 54% Undervalued At a last close of $148.84 versus a narrative fair value near $326, the current price sits far below what the most followed model implies. > _Rapidly rising adoption of Omnipod 5 in both the U.S. and international markets, driven by strong clinical evidence, ease of use, and superior integration with the latest glucose sensors, is positioning Insulet to capture a disproportionately large share of the expanding global diabetes device market, supporting outsized top-line revenue growth for several years._ Read the complete narrative. Curious what kind of revenue growth, margin expansion, and future earnings multiple are built into that fair value? The narrative leans on bold, precise forecasts that many investors will want to stress test for themselves. **Result: Fair Value of $326 (UNDERVALUED)** Have a read of the narrative in full and understand what's behind the forecasts. However, this narrative could unravel if Omnipod 5 device issues escalate, or if patch pump competition and pricing pressure affect revenue growth and margins more than expected. Find out about the key risks to this Insulet narrative. ## Another View: Market Multiple Check The SWS DCF model flags Insulet as undervalued, with the current $148.84 price sitting well below an estimated future cash flow value of about $327. Yet the stock trades on a P/E of 34x, above the Medical Equipment industry at 24.1x and its own 30.6x fair ratio, which points to richer expectations baked into earnings today. That kind of gap can mean either a mispriced opportunity or a sign that cash flow models are leaning too heavily on growth and margin forecasts. Which story do you think fits best? Look into how the SWS DCF model arrives at its fair value. PODD Discounted Cash Flow as at May 2026 ## Next Steps With mixed signals across valuation models and sentiment, it helps to look past the headlines, review the full picture, and decide where you stand. To weigh those concerns and potential upsides side by side, start with the 2 key rewards and 1 important warning sign. ## Looking for more investment ideas? If this Insulet story has you thinking differently about risk and reward, do not stop here when a broader watchlist could surface your next opportunity. - Spot potential bargains early by scanning 47 high quality undervalued stocks that pair quality fundamentals with prices that may not fully reflect them yet. - Prioritize resilience first and review 68 resilient stocks with low risk scores where lower risk scores help you focus on stability before anything else. - Look for under-the-radar opportunities using screener containing 23 high quality undiscovered gems that highlight companies many investors might be ignoring. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### **New:** AI Stock Screener & Alerts Our new AI Stock Screener scans the market every day to uncover opportunities. • Dividend Powerhouses (3%+ Yield) • Undervalued Small Caps with Insider Buying • High growth Tech and AI Companies Or build your own from over 50 metrics. Explore Now for Free ### Related Stocks - [PODD.US](https://longbridge.com/en/quote/PODD.US.md) ## Related News & Research - [UBS Group AG Grows Stock Position in Insulet Corporation $PODD](https://longbridge.com/en/news/285205382.md) - [Resona Asset Management Co. Ltd. Cuts Position in Danaher Corporation $DHR](https://longbridge.com/en/news/286897088.md) - [LifeSci Capital Sticks to Their Buy Rating for MoonLake Immunotherapeutics (MLTX)](https://longbridge.com/en/news/286649191.md) - [LifeSci Capital Sticks to Their Buy Rating for Tenax Therapeutics (TENX)](https://longbridge.com/en/news/286648286.md) - [Corbus Pharmaceuticals (CRBP) Receives a Buy from LifeSci Capital](https://longbridge.com/en/news/286648720.md)